Arikawa Y - Search Results

1

Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.

Miwatashi S, Arikawa Y, Kotani E, Miyamoto M, Naruo K, Kimura H, Tanaka T, Asahi S, Ohkawa S. Miwatashi S, et al. Among authors: arikawa y. J Med Chem. 2005 Sep 22;48(19):5966-79. doi: 10.1021/jm050165o. J Med Chem. 2005. PMID: 16162000

2

Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as p38 MAP kinase inhibitors.

Miwatashi S, Arikawa Y, Naruo K, Igaki K, Watanabe Y, Kimura H, Kawamoto T, Ohkawa S. Miwatashi S, et al. Among authors: arikawa y. Chem Pharm Bull (Tokyo). 2005 Apr;53(4):410-8. doi: 10.1248/cpb.53.410. Chem Pharm Bull (Tokyo). 2005. PMID: 15802841 Free article.

3

Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as selective adenosine A3 antagonists.

Miwatashi S, Arikawa Y, Matsumoto T, Uga K, Kanzaki N, Imai YN, Ohkawa S. Miwatashi S, et al. Among authors: arikawa y. Chem Pharm Bull (Tokyo). 2008 Aug;56(8):1126-37. doi: 10.1248/cpb.56.1126. Chem Pharm Bull (Tokyo). 2008. PMID: 18670113 Free article.

4

Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB).

Arikawa Y, Nishida H, Kurasawa O, Hasuoka A, Hirase K, Inatomi N, Hori Y, Matsukawa J, Imanishi A, Kondo M, Tarui N, Hamada T, Takagi T, Takeuchi T, Kajino M. Arikawa Y, et al. J Med Chem. 2012 May 10;55(9):4446-56. doi: 10.1021/jm300318t. Epub 2012 Apr 30. J Med Chem. 2012. PMID: 22512618

5

Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers.

Nishida H, Hasuoka A, Arikawa Y, Kurasawa O, Hirase K, Inatomi N, Hori Y, Sato F, Tarui N, Imanishi A, Kondo M, Takagi T, Kajino M. Nishida H, et al. Among authors: arikawa y. Bioorg Med Chem. 2012 Jun 15;20(12):3925-38. doi: 10.1016/j.bmc.2012.04.014. Epub 2012 Apr 14. Bioorg Med Chem. 2012. PMID: 22579619

6

Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).

Lam B, Arikawa Y, Cramlett J, Dong Q, de Jong R, Feher V, Grimshaw CE, Farrell PJ, Hoffman ID, Jennings A, Jones B, Matuszkiewicz J, Miura J, Miyake H, Natala SR, Shi L, Takahashi M, Taylor E, Wyrick C, Yano J, Zalevsky J, Nie Z. Lam B, et al. Among authors: arikawa y. Bioorg Med Chem Lett. 2016 Dec 15;26(24):5947-5950. doi: 10.1016/j.bmcl.2016.10.087. Epub 2016 Nov 2. Bioorg Med Chem Lett. 2016. PMID: 27839918

7

Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action.

Nishida H, Arikawa Y, Hirase K, Imaeda T, Inatomi N, Hori Y, Matsukawa J, Fujioka Y, Hamada T, Iida M, Nishitani M, Imanishi A, Fukui H, Itoh F, Kajino M. Nishida H, et al. Among authors: arikawa y. Bioorg Med Chem. 2017 Jul 1;25(13):3298-3314. doi: 10.1016/j.bmc.2017.04.014. Epub 2017 Apr 13. Bioorg Med Chem. 2017. PMID: 28442261

8

Exploration of pyrrole derivatives to find an effective potassium-competitive acid blocker with moderately long-lasting suppression of gastric acid secretion.

Nishida H, Fujimori I, Arikawa Y, Hirase K, Ono K, Nakai K, Inatomi N, Hori Y, Matsukawa J, Fujioka Y, Imanishi A, Fukui H, Itoh F. Nishida H, et al. Among authors: arikawa y. Bioorg Med Chem. 2017 Jul 1;25(13):3447-3460. doi: 10.1016/j.bmc.2017.04.034. Epub 2017 Apr 27. Bioorg Med Chem. 2017. PMID: 28483454

9

Synthetic studies of five-membered heteroaromatic derivatives as potassium-competitive acid blockers (P-CABs).

Arikawa Y, Hasuoka A, Nishida H, Hirase K, Inatomi N, Takagi T, Tarui N, Kawamoto M, Imanishi A, Itoh F, Kajino M. Arikawa Y, et al. Bioorg Med Chem Lett. 2015;25(10):2037-40. doi: 10.1016/j.bmcl.2015.03.094. Epub 2015 Apr 6. Bioorg Med Chem Lett. 2015. PMID: 25891103

10

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.

Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, Hirase K, Kajino M, Inatomi N. Hori Y, et al. Among authors: arikawa y. J Pharmacol Exp Ther. 2010 Oct;335(1):231-8. doi: 10.1124/jpet.110.170274. Epub 2010 Jul 12. J Pharmacol Exp Ther. 2010. PMID: 20624992

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

110 results

Search Page